Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD

Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue disease Pulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need ... Biopharmaceuticals, FDA, Regulatory Boehringer Ingelheim, nintedanib, interstitial lung disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news